Payment overview · 2025
General Payments
$129.50
6 reported records · 5 companies
Healthcare provider profile · identity verified
Audie C Florida, MD
Allopathic & Osteopathic Physicians|Family Medicine · GREENVILLE, NC · NPI 1124145214
Verified facts
What the public records show
CMS Open Payments records show Audie C Florida, MD received $129.50 in general payments during 2025 across 6 reported records.
Abbott Laboratories accounted for 35.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.44 | 35.9% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.29 | 22.6% | 1 | 2025 |
| The Binding Site Inc. | Unresolved — no canonical attribution shown | $19.36 | 14.9% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $19.10 | 14.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.31 | 11.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $129.50 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $46.44 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| Freelite Normalized: freelite |
Device | The Binding Site Inc. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 405 | 97 |
| Atorvastatin Calcium | Atorvastatin Calcium | 327 | 92 |
| Gabapentin | Gabapentin | 223 | 57 |
| Losartan Potassium | Losartan Potassium | 194 | 47 |
| Trazodone Hcl | Trazodone Hcl | 155 | 32 |
| Omeprazole | Omeprazole | 151 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 144 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 34 |
| Lisinopril | Lisinopril | 125 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 117 | 51 |
| Ezetimibe | Ezetimibe | 117 | 29 |
| Januvia | Sitagliptin Phosphate | 116 | 24 |
| Prednisone | Prednisone | 115 | 88 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 29 |
| Celecoxib | Celecoxib | 111 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 17 |
| Montelukast Sodium | Montelukast Sodium | 99 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 93 | 21 |
| Allopurinol | Allopurinol | 89 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 24 |
| Carvedilol | Carvedilol | 82 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 22 |
| Metformin Hcl | Metformin Hcl | 75 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 19 |
| Eliquis | Apixaban | 74 | 18 |
| Meloxicam | Meloxicam | 74 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 15 |
| Pregabalin | Pregabalin | 73 | 25 |
| Terazosin Hcl | Terazosin Hcl | 68 | 13 |
| Ibuprofen | Ibuprofen | 63 | 23 |
| Glipizide | Glipizide | 59 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 14 |
| Furosemide | Furosemide | 54 | 17 |
| Topiramate | Topiramate | 51 | suppressed |
| Ozempic | Semaglutide | 50 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 49 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 48 | 30 |
| Bupropion Xl | Bupropion Hcl | 48 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 17 |
| Tramadol Hcl | Tramadol Hcl | 44 | 23 |
| Baclofen | Baclofen | 43 | 16 |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Valsartan | Valsartan | 43 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 32 |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | 11 |
| Simvastatin | Simvastatin | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 27 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 16 |
| Mupirocin | Mupirocin | 26 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 26 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 19 |
| Alprazolam | Alprazolam | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Famotidine | Famotidine | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nystatin | Nystatin | 13 | 11 |
| Acyclovir | Acyclovir | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Glimepiride | Glimepiride | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | 11 |
| Digoxin | Digoxin | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $129.50 · 6 records | Abbott Laboratories | FREESTYLE LIBRE 3, Flexitouch Plus, Freelite, INTELLIS ADAPTIVESTIM, Nimbl, WaveWriter Alpha Prime 16 | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error